Clinical Trial Detail

NCT ID NCT02599324
Title A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Pharmacyclics
Indications

gastroesophageal junction adenocarcinoma

transitional cell carcinoma

gastric adenocarcinoma

clear cell renal cell carcinoma

colorectal cancer

Therapies

Cetuximab + Ibrutinib

Ibrutinib + Paclitaxel

Everolimus + Ibrutinib

Docetaxel + Ibrutinib

Age Groups: senior adult

Additional content available in CKB BOOST